Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Newron’s failure in Rett syndrome leaves the late-stage pipeline to GW Pharma, Acadia and Anavex.
A phase III Lennox-Gastaut trial sees Fintepla meet statistical significance but fail the test of clinical relevance.
Genmab is seeking data to position tisotumab as its first in-house launch, while Zogenix wants Fintepla to challenge GW in Lennox-Gastaut syndrome.
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
Spending $250m on Modis gives Zogenix a new rare disease niche, but the timing and the target both look odd.